Chinese herbal medicine in treatment of diabetic peripheral neuropathy: A systematic review and meta-analysis

被引:38
作者
Xu, Hong-Bin [1 ]
Jiang, Rui-Hua [3 ]
Chen, Xian-Zhen [2 ]
Li, Ling [1 ]
机构
[1] Tongji Univ, Sch Med, Shanghai Peoples Hosp 10, Dept Clin Pharm, Shanghai 200072, Peoples R China
[2] Tongji Univ, Sch Med, Shanghai Pulm Hosp, Dept TB, Shanghai 200433, Peoples R China
[3] Tongji Univ, Sch Med, Shanghai Peoples Hosp 10, Dept Neurosurg, Shanghai 200072, Peoples R China
关键词
Chinese herbal medicine; Diabetic peripheral neuropathy; System review; Meta-analysis; RANDOMIZED CONTROLLED-TRIALS; EFFICACY; QUALITY; PAIN; AMITRIPTYLINE; PATHOGENESIS; COMBINATION; SAFETY;
D O I
10.1016/j.jep.2012.07.034
中图分类号
Q94 [植物学];
学科分类号
071001 [植物学];
摘要
Aim of study: There are multimodal and multidisciplinary approaches to treat diabetic peripheral neuropathy (DPN). However, the intractable adverse effects limited their widespread use. Chinese herbal medicine (CHM) is increasingly used for the treatment of DPN. The aim of this study was to review existing evidence on the effectiveness of CHM for the treatment of DPN. Materials and methods: Searches were performed with Medline, Embase, Cochrane Central Register of Controlled Trials, CNKI, CBM and Wangfan databases. Controlled trials comparing CHM with other medicine for the treatment of DPN were analyzed. Results: Eighteen trials met the inclusion criteria. All trials used vitamin B12 and/or B1 as control. Clinical therapeutic effect, divided by three grades including marked effective, effective and ineffective according to the improved degree of subjective symptom, tendon reflex, and nerve conduction velocity, was the only end point reported in all trials, and thus evaluated. The results showed CHM treatment was associated with a superiority in marked effective (odds ratio [OR] 2.40; 95% confidence interval [CI]: 0.94 to 2.97; p < 0.001), and effective (OR, 1.39; 95% CI: 1.16 to 1.67; p < 0.001). Patients who received CHM treatment was associated with a less likely to report ineffective (OR, 0.26; 95% CI: 0.21 to 0.33, p < 0.001). No adverse events were reported in any of the included trials. Conclusions: According to the pooled results of our study and the poor quality of the included trials, it might be uncertainty that there was a superiority of CHM for treating DPN. More rigorous controlled trials are required to substantiate or refute these early findings. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:701 / 708
页数:8
相关论文
共 47 条
[1]
[Anonymous], AM J MED
[2]
Epidemiology, public health burden, and treatment of diabetic peripheral neuropathic pain: A review [J].
Barrett, Amy M. ;
Lucero, Melanie A. ;
Le, Trong ;
Robinson, Rebecca L. ;
Dworkin, Robert H. ;
Chappell, Amy S. .
PAIN MEDICINE, 2007, 8 :S50-S62
[3]
PERIPHERAL DIABETIC NEUROPATHY [J].
BAYS, HE ;
PFEIFER, MA .
MEDICAL CLINICS OF NORTH AMERICA, 1988, 72 (06) :1439-1464
[4]
Diabetic neuropathies - A statement by the American Diabetes Association [J].
Boulton, AJM ;
Vinik, AI ;
Arezzo, JC ;
Bril, V ;
Feldman, EL ;
Freeman, R ;
Malik, RA ;
Maser, RE ;
Sosenko, JM ;
Ziegler, D .
DIABETES CARE, 2005, 28 (04) :956-962
[5]
Metabolic and vascular factors in the pathogenesis of diabetic neuropathy [J].
Cameron, NE ;
Cotter, MA .
DIABETES, 1997, 46 :S31-S37
[6]
Chen R.S., 1999, HEBEI J TRADITIONAL, V21, P353
[7]
Systematic reviews: Synthesis of best evidence for clinical decisions [J].
Cook, DJ ;
Mulrow, CD ;
Haynes, RB .
ANNALS OF INTERNAL MEDICINE, 1997, 126 (05) :376-380
[8]
Opioids for neuropathic pain [J].
Eisenberg, E. ;
McNicol, E. ;
Carr, D. B. .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2006, (03)
[9]
Efficacy and safety of opioid agonists in the treatment of neuropathic pain of nonmalignant origin - Systematic review and meta-analysis of randomized controlled trials [J].
Eisenberg, E ;
McNicol, ED ;
Carr, DB .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 293 (24) :3043-3052
[10]
Fu J., 2004, INFORM TRADITIONAL C, V21, P24